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Abstract
In the past 15 years, the incidence of Clostridium difficile infection has emerged especially 
because of the new highly virulent strains. The classical diagnosis methods used to diag-
nose C. difficile infection take time and the enzyme immunoassay (EIA) test has demon-
strated the lack of sensitivity. Even though new modern molecular methods have become 
available, the diagnosis of C. difficile in patients or healthy carriers remains a big challenge 
for both clinicians and laboratory staff. In the present chapter, we will list the main geno-
typing methods, stressing their advantages and disadvantages, as well. A brief presenta-
tion of the most useful kit (principle, sensitivity, specificity, benefits and disadvantages) 
to assess the impact of molecular methods in comparison with classical methods will 
offer support for future research in the present context of an increasing prevalence of 
C. difficile infection that represents worldwide, a real public health problem. To improve 
the patients’ quality of life, to limit hospital transmission, and to save money, we have 
tried to identify the best diagnosis algorithm as tool in C. difficile diagnosis and surveil-
lance. This algorithm may differ depending on the capacities of the laboratories and on 
the socioeconomic level of the countries in question.
Keywords: C. difficile, molecular method, PCR, RT-PCR, REA, PFGE, MLVA, VNRT, 
MLST, typing, diagnosis algorithm
1. Introduction
In the last years, especially starting with the early 2000s, the Clostridium difficile infection (CDI) 
has become a top subject in the medical field all over the world because of both high preva-
lence of healthcare-associated infection (HAI) and community infection. The causes of these 
spectra, including colonization and the diversity of clinical pictures, are topics of different 
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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chapters and, for this reason, we approach the subject directly. For a better understanding of 
the biological methods, the readers must look first at the genetics chapter.
The growing incidence of the infection with C. difficile around the globe, especially 
because of the highly virulent strains, has changed the approach of laboratory diagno-
sis and imposed the drafting of numerous guides, which include preventive measures 
to stop their circulation [1]. Different expert groups, published in the last years large 
studies on the national programs for C. difficile surveillance, coming to the conclusion 
that many countries do not have the capacity to quickly diagnose the C. difficile infec-
tions, and that hospital outbreaks led to a continuous spread of the strains, including 
the highly virulent ones [2]. In countries as Romania, Bulgaria, and Greece, in which the 
Eurosurveillance studies (run by EUCLID) concluded the low-level capacity of laborato-
ries, in the last years, at national level, the experts have initiated the implementation of 
a new guide to improve the surveillance of C. difficile [2, 3]. The apparent low incidence 
of CDI in some countries, such as China, is the consequence of the limited laboratory 
diagnosis capacities [4].
The overuse of antibiotics and the long and repeated hospitalization, especially in the case 
of patients over 65, are the main causes of this increase [5]. This change is mainly related to 
the high diversity of virulent strains and to the new approach of the antibiotic therapeutic 
scheme [6]. A long list of antibiotics, including the large broad spectrum, may be the cause 
of the dysbiosis that lead to CDI: clindamycin, cephalosporins (e.g., cefaclor, cefotaxime), 
β-lactams (e.g., penicillins, ampicillin, amoxicillin-clavulanic acid), fluoroquinolones, includ-
ing last generations of gatifloxacin, levofloxacin, and moxifloxacin [5, 7, 8]. Not all authors 
accept the whole list; some of them consider cephalosporins to be certainly involved, whereas 
others consider fluoroquinolones (cited by Daniel and Rapose [9]). CDI was noticed even 
after short-term antibiotic courses, inclusively as a preventive measure [5]. Since 2002, the 
most virulent strains of C. difficile, described in literature as toxinotype IIINAP1/027, were 
isolated as resistant to fluoroquinolones [7]. The 027 toxinotype nomination is related to labo-
ratory methods, pulsed field gel electrophoresis (PFGE), and to the place of isolation (North 
American PFGE type 1 (NAP1), respectively). This resistance pattern is associated with the 
ability to produce A and B toxins in larger quantities, including binary toxin production, and 
has a greater capacity to spread endemically [6].
The Center for Disease Control and Prevention (USA, Atlanta) consider CDI as the first 
cause of healthcare-associated infection [10]. All authors agree that CDIs are related to 
C. difficile strains, which produce toxins (A, B, and binary toxin, and many other virulence 
factors) [11, 12].
With the new virulence strains that have emerged, the incidence, morbidity, and mortality 
through CDI have increased all over the world, especially in the developed countries, start-
ing with the early 2000s [13]. In USA, CDC estimated that a quarter million people need 
hospitalization and around 5.6% die from CDI each year; more than 90% of deaths occur in 
people over 65 years, but almost 50% of the infections were noted in patients younger than 
65 [10]. In parallel with the overuse of antibiotics, many old patients have co-morbidities 
that increase the risk of severe evolution; on the other hand, the need for quick, sensitive, 
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and specific diagnosis have led to new laboratory techniques, including high-level biologi-
cal and molecular ones that improved the positivity rate, decreasing the false negative one. 
All these factors, together with the previously mentioned and, probably, with other fac-
tors (e.g., pump protons inhibitors) made that, only from 2000 to 2007, the death number 
related to CDI to increase with 400% [10]. In the intensive care unit (ICU), the prevalence 
of CDI is the highest because it cumulates many risk factors. An excellent meta-analysis, 
from 2015, concluded that the prevalence of CDI among diarrheic ICU patients is more 
than five times higher in comparison with ICU patients with risk for pseudomembranous 
colitis, after approximately 10.5 days. The mortality rate was also higher: 32 versus 24%. 
This higher morbidity and mortality rate from ICU requires additional measures in order 
to prevent the spread of infections and more expensive regimens [14].
Even though the number of studies conducted to find out the costs of medical burden have 
increased, only a few of them have considered all factors that influence healthcare-associated 
costs; briefly, the CDC considered “at least $1 billion in excess medical costs per year” [10], 
and Kyne et al. estimated that C. difficile diarrhea cost/case was around $4600 and, using the 
appropriate statistics analysis, concluded that, in the USA, the total annual cost for diarrhea 
treatment exceeds $1.1 billion [15]. Some authors have considered different algorithms for 
diagnosis using phenotypic and biological molecular methods, concluding that the mod-
ern methods are less expensive than the traditional diagnostic ones recommended by some 
guides [16]. The risk of rapid spread in healthcare facilities of highly virulent strains, includ-
ing those resistant to antibiotics, has led to improved laboratory techniques that have become 
able to quickly highlight CDI, with the possibility of applying the most appropriate preven-
tive measures and modified therapeutic schemes [17, 18].
2. Arguments for the rapid diagnosis of C. difficile infection/colonization 
by molecular methods
The rapid diagnosis by molecular methods is costly at first sight, when compared to the 
rapid detection of toxins by enzyme immunoassay (EIA) or glutamate dehydrogenase (GDH) 
detection (an antigen produced in high amounts by all C. difficile strains, including the non-
toxigenic one). Even though the EIA is a cheap test and despite the different commercial 
variants available, the specificity varied from 40 to 100% [13], with no major consequences 
regarding the clinical impact because a positive NAAT cannot differentiate between infec-
tion and colonization (Table 1). For this reason, it is necessary to also test the biomarkers 
that suggest the active infection. Different biomarkers were used, e.g., fecal lactoferrin and 
calprotectin, or cytokine analysis, but they did not demonstrate an efficient support in this 
differentiation [13].
In the modern era, when molecular platforms play an important role in patient diagnosis and 
management cases, a clear approach must be taken into consideration in order to use this tool 
in the best way, to reach as soon as possible a sensitive and specific diagnosis for patients 
and to reveal the most useful epidemiological markers, to initiate appropriate preventive 
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 measures. To reach this goal, may become difficult because many years after the emergence 
of the new virulent strain (027 type) in parallel with others, which are eventually antibiotic-
resistant (e.g., moxifloxacin-resistant, ribotype 012, 017, and 046 isolated from Sweden) [17], 
some authors highlight the lack of consensus regarding case definition, sampling, and diag-
nosis step algorithms [18, 19].
2.1. Direct detection of C. difficile in clinical specimens by molecular platforms
Different protocol algorithms use two or three steps to improve diagnosis sensitivity and 
specificity, looking to the lowest cost as well. In two-step algorithm that includes as first test 
the GDH detection, the negative test proves the absence of C. difficile. For the positive test, the 
EIA and/or the nucleic acid amplification test (NAAT) can be used as confirmatory tests. In 
the two-step algorithm, the NAAT is used after the GDH detection, and the positive test will 
impose the patient’s isolation and the preventive methods to stop the transmission. The two-
step algorithm may fail in CDI diagnosis, the GDH detection being related to the test sensitiv-
ity (79–98%) (Shetty et al., cited by Tenover et al. [20]); low sensitivity is related to different 
nontype 027 strains [20].
For the three-step variant, the EIA is used as confirmatory test and for negative results, and 
the NAAT is necessary to confirm or note the negative results (Figure 1).
Using directly molecular methods, the C. difficile diagnosis rates become twofold higher in 
comparison with EIA alone. Soon after that, the incidence of C. difficile increased but decreased 
afterward, probably because the experts used new case definitions, and better preventive 
methods can explain the transmission decline in hospitals. After many years of using in paral-
lel different diagnosis algorithms, there are no sufficient data to support a clear conclusion 
regarding the clinical benefit and hospital costs. Larson et al.’s study concludes that PCR 
alone can save around 200,000 USA dollars annually, mainly by removing several tests [21]. 
Burnham and Carroll clearly mentioned that the need of future cost-efficient studies relates to 
NAAT testing alone [22, 23].
Phenotypical methods Toxin A/B tested by EIAs
Glutamate dehydrogenase antigen (GDH)
EIA screen—GDH/toxin
Lateral flow, Membrane assay
Cell culture cytotoxin neutralization assays (CCCNA)
Toxigenic culture (Culture + Cytotoxin assay) “Gold 
standard”
Molecular methods Molecular strains typing
PCR amplification
Sequence-based
Table 1. Main techniques for the detection of C. difficile [13].
Clostridium Difficile - A Comprehensive Overview76
3. Molecular methods applicable to C. difficile diagnosis
Until now, it has been clearly stated that molecular tests improve the detection of C. difficile 
in samples (stools, respectively), but that gene detection is not always a proof of their pheno-
typic expression. A few studies have tried to correlate gene detection with toxin expression 
using sequence analysis: some of them have found a major advantage for amplification meth-
ods in comparison with the EIA and GDH detection for the 027 isolates, but the small number 
of ribotypes belonging to the non-027 strains seems to be the main cause for test similarity 
results for this category [13] (Table 2).
Figure 1. Algorithm steps for C. difficile diagnosis—different laboratory approaches.
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Method Comments References
AP-PCR Advantages: It is a reproducible, rapid, and simple technique
It is sensitive and accurate, comparable with immunoblotting and REA, for the 
identification of C. difficile
Applicability: In clinical laboratory, for strain identification
Approximated time: 36–48 h; it is cost-efficient, especially for healthcare facility 
outbreak investigations
Cost: $150–200 per specimen, when duplicate reactions with two sets of primers are used
Disadvantages: Low reproducibility
[26–28, 36]
PCR 
ribotyping
Two sets of primers were proposed (USA versus UK)
It is the reference standard method for C. difficile strain typing in Europe
Advantages: Discriminatory power
Applicability: Laboratory with moderate equipment
Disadvantages: Moderate typability, reproducibility, ease of interpretation, and 
transportability
[10, 28, 33, 
37, 54]
Repetitive 
extragenic 
palindromic 
sequence-
based PCR
(rep-PCR)
It uses heterogenous PCR primers that target noncoding repetitive sequences from the 
C. difficile genome
Advantages: It is highly reproducible and more discriminatory than PCR ribotyping
Applicability: C. difficile ribotyping
Disadvantages: Even though the results for ribotypes 027 and 001 were excellent correlated 
with the PFGE and PCR ribotyping, for other types, it showed a reduced concordance. In 
the same studies, the method failed to separate between these two ribotypes
Semiautomated variant (DiversiLab): Better standardization and reproducibility than 
the manual rep-PCR
[33, 37]
REA It uses the HindIII enzyme in most of the protocols; a large number of bands can be 
separated by classical gel electrophoresis
Applicability: It has been proved to be a very useful method for epidemiological 
studies, with an excellent discriminatory capacity and reproducibility
Disadvantages: It is difficult to interpret band patterns, and protocols are difficult to 
compare between laboratories
[33, 35]
PFGE The most frequent method used for C. difficile strain typing, as support for outbreak 
investigations
Advantages: It is the “gold standard” method for C. difficile typing, as well as for 
other bacterium strains, and it is as comparative method between laboratories; it is a 
discriminatory and reproducible method, even though some strains are not typified
In a modified protocol, the number of nontypeable strains has become 0, and both 
advantages were similar
It is the reference standard in the USA
Applicability: control of epidemic outbreaks
Disadvantages: Needs longer time, it is more expensive, and it is designated for 
expertise laboratories because of the difficulties in the inter-laboratory comparison
[33–35, 37, 
38]
Toxin-typing 
RFLP
It is based on the capacity of the C. difficile genome to encode a synthesis of minimum 
two toxins (A and B) (pathogenicity locus-PaLoc), and it is defined “as a group of strains 
with identical changes in the PaLoc when compared with the other strains,” additional 
toxins (tcd C, tcdR, tcdE) and, for some strains, binary toxin too. There are 32 toxinotypes 
(some of them described as “minor,” and 0 type) (from reference strain VPI10463)
The current method for toxinotyping is restriction length polymorphism (RFLP)
Advantages: Highly reproducible
Applicability: In well-equipped laboratories for epidemiological studies. Toxinotypes 
III, IV, V, VIII, IX, and XII, the most frequent isolated from humans (VIII and IIIb [BI/
NAP1/027 strains], are associated with disease severity and have been isolated worldwide)
Disadvantages: Lack of consensus standards, difficult interpretation
[33, 39–42, 
45]
Table 2. The main biological molecular methods for C. difficile infection diagnosis.
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3.1. Amplification methods
For many years, the nucleic acid amplification tests (NAATs) have been used to detect C. dif-
ficile in fecal samples as an efficient tool to replace nonmolecular methods such as EIA and 
GDH; the first publication appeared in the early 1990s and the conventional PCR methods 
had as target the different genes (e.g., tcdA, tcdB, and 16S rRNA genes, respectively) [13, 22].
The emergence of the new C. difficile virulent strains and the low sensitivity and specificity of 
the phenotypic methods have imposed their replacement with molecular methods, starting with 
genotyping and strain typing, respectively. In a very well-documented presentation of these 
methods, Dingle and MacCannel [24] proposed a list of typing methods. Briefly, these methods 
are restriction fragment methods (restriction endonuclease analysis [REA], pulsed field gel elec-
trophoresis [PFGE], toxinotyping, PCR amplification methods [PCR ribotyping], repetitive extra-
genic palindromic PCR [rep-PCR], multilocus variable-number tandem repeat analysis [MLVA], 
arbitrarily primed PCR [AP-PCR], and sequence-based methods, including the whole genome 
sequencing [WGS], target sequencing approaches, multilocus sequence typing [MLST], surface 
layer protein A sequencing [slpA], tandem repeat sequence typing [TRST], single nucleotide 
polymorphism typing [SNPT], whole genome multilocus sequence typing, and the Kmer-based 
comparison).
From these methods, we are presenting the one with the highest clinical applicability, and 
for the most important of them, we have conducted a synthesis of recent scientific literature 
(PFGE, ribotyping, MLVA, and sequence-based methods). We are concluding this presenta-
tion of methods for C. difficile detection by presenting the FDA commercially approved tests, 
which have the advantage of accuracy, reproducibility, and clinical validation by comparing 
different laboratories from different countries.
Finally, we will list the main contribution of the molecular methods regarding the antibiotic 
resistance surveillance, the comparison between the biological molecular methods and a com-
parison between the classical rapid detection tests (EIA, DGH) versus the modern biological 
molecular methods.
3.1.1. The arbitrarily primed PCR or AP-PCR
It is a simple and rapid method to detect different bacteria outbreaks [25]. The AP-PCR 
belongs to the early stages of biological molecular era and uses a selection of primers that, at 
low annealing temperatures, produced a variety of bands. Details regarding the patent of this 
technique (Arbitrarily primed polymerase chain reaction method for fingerprinting genomes; United 
States Patent 6696277) can be found in (http://www.freepatentsonline.com/6696277.html) [26].
Advantages—AP-PCR provides a rapid and sensitive screen for the determination of clonal 
relationships among C. difficile strains [27]. The comparative studies using PCR ribotyping 
and AP-PCR from the cited authors (e.g., McMillin, 1992; Van Belkum, 1993, 1994) used previ-
ous study primers (Van Belkum, 1994) and demonstrated that for samples in which the DNA 
was severely affected and the RFLP was unable to recognize fragments, the AP-PCR was able 
to provide clear typing results [28].
Clostridium difficile Infection Diagnosis by Biological Molecular Methods
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Disadvantages—It is less reproducible than the PCR ribotyping and, for this reason, it is recom-
mended as the best typing method, even though it has concordant results with the AP-PCR [27]. 
The AP/PCR and the RAPD (random amplified DNA, that uses short primers) were not accepted 
later as comparative interlaboratory methods because of their difficulties in control and stan-
dardization (Colliers et al., cited by Gürtler and Grando [29]).
3.1.2. Restriction endonuclease analysis (REA)
In one of the first articles (1987) that related to the REA, Wren and Tabaqchali used HindIII as 
cutting enzyme and concluded that analyzing the DNA with it is a very sensitive method for 
C. difficile strain differentiation and a tool for epidemiological studies. Other restriction enzymes, 
such as BamHI, EcoRI, SalI, and SmaI, were less useful in a clear separation of bands [30]. In a 
very well cited paper [31], two extraction methods were used, and the 206 REA types were clas-
sified into 75 groups; they concluded that the REA is a rapid, very sensitive, discriminatory, and 
reproducible method for C. difficile typing, and recommended its use in large epidemiological 
studies. Using this efficient tool, different authors have also identified outbreaks from North 
America in USA and in Canada, respectively [7, 32]. Using the biological molecular methods, 
different study groups have clearly noted that the main strain that is spread over the world 
(Europe, USA, etc.) is known as BI/NAPI/027 because of different methods used to identify it 
(e.g., type BI, using REA; “NAP1,” from the NA, North America, and P, from pulse-field type 1, 
using as method the PFGE; and 027 by PCR-ribotyping) [7, 31]. The REA is a relatively simple 
method for analyzing the total genomic DNA and has been successfully applied to several 
bacterial species, including C. difficile. Among the major advantages, we can note its good dis-
criminatory capacity, but the main concern is related to the numerous restriction fragments that 
are generated, especially fragments smaller than 11 kb [33]. It is difficult to compare the method 
between laboratories, and its high-level protocol technicity required a high-level expertise [24].
3.1.3. Pulse field gel electrophoresis (PFGE)
For years, the epidemiology and clinical case management were imposed on C. difficile strain 
typing. Even though the PFGE was one of the first used methods in some regions as North 
America, it is still considered as being a standard method. In short, the PFGE supposed DNA 
digestion with restriction enzymes (e.g., Smal) and agarose gel electrophoresis for DNA frag-
ment separation and characterization. After that, an electric field is being changed repeatedly, 
using three directions. The large DNA fragments that cannot be clearly separated by classical 
gel electrophoresis are separated by an electric field that changes directions many times in 
12–24 h. In literature, this clearer band pattern is known as the “North-American pulsed-field,” 
or as the NAP types. One pulsotype is defined as that with more than 80% similarity, in inter-
preting such bands, we must bear in mind the subjectivity of interpretation and the fact that, 
sometimes, we cannot differentiate between the studied strain and the reference strains that we 
used for comparison [13]. The PFGE was the method used by many researchers, some of them 
looking at the comparability degree, using different methods (e.g., MLVA, REA, and PFGE); for 
example, Killgore et al. find that the D value (discriminatory index score) for PFGE is 0.843; in 
the cited study, the D varied between 0.964 and 0.631, and they recommend as reference meth-
ods, the REA and the MLVA, for their discriminatory capacity [32]. Even though it is considered 
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as a “gold standard,” the method has changed the protocol over the years and many protocols 
have been suggested (Corkill et al., 2000; Herschleb et al., 2007) [34, 35].
From the PubMed database, using the next keyword—PFGE C. difficile human infections—we 
have selected 48 articles, published between 1994 and 2017. In time, the PFGE has been used 
by researchers in different clinical and laboratory applications.
Starting with the 1990s, many authors have compared the PFGE with other molecular methods 
used to analyze C. difficile [33, 36, 37]. Some of them have concluded that the PFGE had compara-
ble discriminatory powers for epidemiologic typing of C. difficile isolates and that the ribotyping 
is appreciably less discriminatory [33], whereas others have found that the PCR-based methods 
were easier and quicker to perform, but their fingerprints were more difficult to interpret than 
those of the PFGE [36].
Pasanen et al. concluded that PFGE and classical PCR ribotyping can be used as reference 
methods in epidemiological studies to confirm the results obtained with other methods. 
Because of the discrepancies between studies (e.g., some authors recommend REA and MLVA 
[32] for C. difficile typing, while others recommend PFGE and conventional PCR [37]), it is 
obvious that further studies and long periods of time are needed in different large geographi-
cal areas for the results to be statistically significant.
Another research team has detected C. difficile in infections other than the very well-known 
antibiotic-associated diarrhea, like the infection of a prosthetic joint [38] in association with 
inflammatory bowel disease [39] in which, interestingly enough, the nonclonal distribution 
of distinct strains was further demonstrated by the PFGE genomic fingerprinting. A team 
from Ohio, USA, published two cases of C. difficile bacteremia, which is a rare event. In one of 
the cases, the bacteremia was caused by the North American pulsed field gel electrophoresis 
(PFGE) type 1 (NAP-1) strain [40].
In the natural history of C. difficile infection, it is important to establish if the infection is a singular or 
a recurrent one of relapse or re-infection [41, 42]. The same method (PFGE) has been used to identify 
host and bacterial factors associated with healthcare-associated acquisition of C. difficile infection 
and colonization. Among patients with healthcare-associated C. difficile infection and those with 
colonization, 62.7 and 36.1%, respectively, had the North American PFGE type 1 (NAP1) strain [43].
In 2006, Kuijper et al. [44] concluded that the increased virulence of C. difficile is probably related 
to the association with antibiotic resistance because the fluoroquinolone-resistant strains are also 
highly toxigenic; these strains belonging to the ribotype 027 (toxinotype III) have been isolated in 
the last years from many countries, from hospitals (e.g., in England and The Netherlands, from 
75 and 16 hospitals, respectively), and from healthcare facilities (e.g., Belgium and France) [44]. 
After this ECDC report, other authors have detected the rapid spread of C. difficile NAP1/027 in 
Brazil [45], Korea [46], Hong Kong [47], Latin America (Chile) [48], and Romania [49].
If the previously mentioned authors have associated the C. difficile strain NAP1/027 with 
recent outbreaks in North America and Europe, characterized by more severe disease symp-
toms, higher mortality rates, and greater risk of relapse, Sirard et al. [51] studied, in a nonout-
break situation, whether specific strains, such as NAP1/027, were associated with more severe 
disease symptoms, higher toxin production, and/or greater sporulation in vitro. Their results 
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suggested that some NAPI/027 strains can be isolated from less severe cases, and even though 
those strains produce large toxin amounts, probably other factors explain better the patients’ 
evolution, and that future studies are necessary to clarify this discrepancy [50].
3.1.4. PCR ribotyping
The strain typing method must be used for epidemiological reasons; in Europe, the ribotyping 
is the most used method in C. difficile identification. For amplification, this method uses one 
fragment from the most constant region, from 16S to 23S RNA genes, the so-called intergenic 
spacer. In this operon, there are many copies from the genome of C. difficile and, using a single 
primer pair, we can obtain different bands with sizes from 200 to 700 bp [13, 37, 52]. For their 
evidence, viewing and comparing, we can use the migration in agarose gel, with commercial 
kits or their analysis with a dedicated software [32, 36, 51, 52].
The definition of Gürtler and Grando [29] seems to briefly and completely describe one of the 
most useful method in C. difficile typing, first introduced by Gürtler (1993), when an original 
primer set, given to large fragments, was very difficult to differentiate in agarose gel electro-
phoresis; later, different authors have tried to overcome these difficulties, and, finally, Bidet et 
al. (1999) used the appropriate primers (located nearest to ITS1). When the gel electrophoresis 
was used to separate the amplified bands, their patterns were difficult to interpret. Despite 
these disadvantages, the low price, the high sensitivity, and specificity were listed as the main 
positive arguments for the simple gel electrophoresis [29].
One major disadvantage of this method is the difficulty to compare the results from different 
laboratories and the lack of unique software analysis. In order to make this method applicable in 
all laboratories and increase the reproducibility, the high-resolution capillary gel electrophoresis 
was called on [53]. To standardize the method in countries like the UK, different laboratories have 
started using the unique protocol [13], including the differentiation of some types (such as the 014 
and the 020) that cannot be distinguished using the conventional agarose gel-based PCR ribotyp-
ing. To increase the discriminative capacity, the capillary gel electrophoresis can be used, includ-
ing for the subtyping of the 014 type characterization [54], variant that also needs standardization.
CDI is a major issue of concern in Europe and USA. For surveillance studies, even though 
reporting the CDI is not mandatory in all EU countries, the ECDC, as CDC Atlanta advises, 
initiates large surveillance programs to decrease the incidence and severity of CDI [55].
In a comprehensive review, with the permission of Public Health England, the authors pub-
lished the prevalence of C. difficile ribotypes, detected from 2007 to 2011. The decreasing order 
of ribotypes was 27, 001, 106, 015, 002, 078, 014, 005, 023, 016, 014/020, 020, 017, 026, 017, 026 [13]. 
Since then, many authors have published their results, specific for their countries: PCR—ribotype 
018 (Italy) [57], ribotype 176 (the Czech Republic) [58], the first two C. difficile ribotype 027/ST1 
isolates being identified in Beijing [59], the PCR-ribotype 176 in Prague [60], another four PCR-
ribotypes (027, 033, 078, and 126) in Italy [61], ribotype 258 (Qatar) [62], the first Polish ribotype 
027 [63], ribotype 126 in Southern Taiwan [64], and ribotype 244— Australia [57, 65]. The preva-
lence of CDI with different ribotypes worldwide underscores the importance of local surveillance 
in detecting and controlling C. difficile infection.
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Few countries are performing follow-up studies on C. difficile ribotype’s recurrence and 
relapses [66]. In Sweden, 29 patients were positive in at least one of the follow-up tests; 16 had 
the same ribotype in follow-up tests, i.e., relapse, and 13 patients with a different ribotype, i.e., 
re-infection [67]. In a recent study (USA) [68], conducted in a small study group, 25 patients 
respectively, 5 of them were colonized and only 3 were classified as recurrent cases (12%). All 
eight patients had risk factor healthcare exposure, and no other risk factors were identified 
(e.g., antibiotics or proton pump inhibitor treatment); neither of them was diagnosed with the 
027 ribotype in the follow-up period. By comparison, Komar et al. (2016, UK) has monitored 
patients with C. difficile infection over a 2-year period, and they found that the epidemic C. dif-
ficile 027/ST1 caused the majority of infections during the sampling period [69].
Another application of ribotyping is testing the susceptibility of C. difficile to antibiotics, 
according to the known virulence of specific ribotypes [69, 70]. Moreover, a team from the UK 
has implemented the antimicrobial stewardship, which is a key component in the reduction of 
healthcare-associated infections, particularly of the C. difficile infection (CDI). They have suc-
cessfully restricted the use of cephalosporins and, subsequently, of fluoroquinolones. From 
an endemically high level of >280 cases per year in 2007–2008, the number of CDIs decreased 
to 72 cases in 2011–2012 [71]. The same antimicrobial stewardship program was used in 
Austria, where the ribotype 027 is prevalent. The reduction of moxifloxacin use, combined 
with provided structured information on CDI, was associated with an immediate decrease of 
CDI rates in this large community teaching hospital [72].
3.1.5. Multilocus variable-number tandem repeat analysis (MLVA)
A different typing method had no high discriminatory capacity, and new techniques were 
in place to overcome this disadvantage bearing in mind that, in the epidemiological inves-
tigation of different outbreaks, it is essential to identify the source of infection/etiological 
agent and its connection with secondary cases. The MLVA based on the amplification of 
different size fragments that can be easily seen using the capillary gel electrophoresis 
and the automated analysis of amplified fragments is one of them [55, 56]. In this large 
study from Europe that included laboratories from different countries, the MLVA was 
used to trace the 027 ribotype. Using the MLVA’s capacity to discriminate and to monitor 
the transmission events in the hospital or in healthcare facility settings, many research 
groups used the MLVA [13, 54, 55, 73–78]. Different studies have concluded that despite 
its high discriminatory capacity, the MLVA is not a standardized method and that, for 
future inter-laboratory comparability, further large studies must be run across the world, 
using an identical protocol.
In the recent years, numerous teams have used the MLVA in many approaches. A research 
group from the Netherlands described the clinical and the microbiological characteris-
tics of CDI among hospitalized children, using the MLVA. They have concluded that the 
C. difficile PCR ribotype 265 was most prevalent in children, this strain being rarely found 
in other countries, except for Belgium. The MLVA showed genetic relatedness between 
three-fourths of pediatric and adult ribotype 265 strains, without a clear epidemiological 
link [79].
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Using the same MLVA Assay, Krutova et al. have performed a survey in 18 hospitals in the 
Czech Republic. They have found the spread of two C. difficile PCR ribotypes within 18 hospitals, 
underlying the importance of standardizing the CDI testing protocols and implementing the 
mandatory CDI surveillance in the country [80].
Kullin et al. have found that identical MLVA types occurred in different wards over time 
and that several patients were infected with identical strains. The patient-to-patient transfer 
and the unique infection events might cause the predominance of ribotype 017 strains in the 
cohort. The multidrug-resistant strains are a potential reservoir for future infections [81].
Usui et al. have analyzed the C. difficile prevalence among piglets in Japan to clarify the infection 
origin and the extent of the associated risk by using molecular and microbiological methods 
for both swine and human clinical and foreign isolates; the MLVA was able to connect the 
European 078 ribotype source, spread in Japan by imported pigs [82].
The MLVA was also used to identify the first case of C. difficile RT027 infection in the Czech 
Republic (CZ), the patient having previously been hospitalized in Germany, prior to moving 
to CZ [83].
A team from the UK (Oxford) has run a comparison between the MLVA and the WGS, and 
they have found that both methods were very similar despite the fact that they have analyzed 
different parts of the bacterial genome. With improvements in the WGS technology, it is likely 
that the MLVA locus data will be available from the WGS in the near future [84].
Another application of the MLVA has been put into practice in the Netherlands, where the 
authors have encountered an outbreak because of these two types occurring simultaneously 
in a 980-bed teaching hospital. The clonal dissemination has been investigated by the MLVA 
that showed persistent clonal dissemination of types 017 and 027 despite the appropriate 
infection control measures [77].
Manzoor et al. have developed in the UK an eMLVA (extended) scheme, which provides 
insight into the genetic diversity of the C. difficile population at both global and cross-infection 
clusters in patient levels, with the possibility of replacing the PCR ribotyping. This eMLVA 
scheme could discriminate clinically significant clusters, while maintaining a good concor-
dance with the PCR ribotyping. The typing schemes containing only seven loci showed, in 
contrast, poor association with the PCR ribotyping [85].
3.1.6. Multiplex nucleic acids test
Sometimes, the C. difficile strain diversity makes the classic PCR fail in identifying different 
types of isolates (some producing both toxins encoded by their genes, tcdA, tcdB, and some 
not, including binary toxin, mediated by the cdtA gene). The real-time PCR multiplex type has 
been put into practice by different researchers [86] or a real-time variant, fluorescence-based 
multiplex PCR, to simultaneously detect tcdA and tcdB genes in the patients’ stools [87].
The C. difficile genome imposed the simultaneous detection of several genes: tcdA, tcdB, 
binary toxin, and Δ117 (single pair deletion at 117nt in tcdC gene), for the detection of the 027 
ribotype (known as the epidemic strain 027/NAP1/PI, respectively). In the last decade, the 
FDA have approved or cleared many NAATs, including the multiplex type. Some of them 
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are  loop-mediated isothermal amplification assays—LAMP—(e.g., Illumigene, Meridian 
Bioscience, Inc., that detect the tcdA gene from the conserved region), helicase-based amplifi-
cation (e.g., Portrait Cdiff Assay, Great Basin; AmpliVue Cdiff Assay—Quidel Corporation), 
or based on array technology (e.g., Verigene Cdiff Assay, Nanosphere, a multiplex one, that 
uses PCR-amplified DNA in a nanoparticle-based assay, able to detect the tcdA and tcdB 
genes, the binary toxin gene, and the Δ117) [88]
The Verigene C. difficile Nucleic Acid Assay has a high sensitivity (98.7%), and a relatively 
low specificity (87.5%) compared to direct cultivation as the gold standard method, and it 
is recommended to be used as a test for the 027 ribotype identification, having been able to 
detect the previously listed markers [88].
3.2. The main sequence-based method for C. difficile
3.2.1. Multilocus sequence typing
In the last years, the MLST has become one of the most accurate methods, especially for 
the identification of different pathogens, including C. difficile, using the internal fragments 
of seven genes. The higher accuracy is related to these allele fragments that have different 
lengths (from 300 to 600 bp) and are easy to arrange precisely with the support of the auto-
mated DNA sequencer, in both strands. For each housekeeping gene, the different sequence 
present in each species genome will be given as distinct allele, for each isolate [13, 89, 90]. 
MLST generates high-throughput sequence data that can be uploaded from laboratories 
worldwide to a common web database [55].
C. difficile is theoretically well suited to MLST, as the species are relatively genetically hetero-
geneous. In 2004, MLST was introduced to study the population structure and global epide-
miology of C. difficile (aroE, ddl, dutA, tpi, recA, gmk, and sodA), in order to analyze a group of 
C. difficile isolates [13, 90, 91, 92]. A major advantage of sequence-based typing methods like 
MLST is the ease of interpretation of the generated data. The sequence data are unambiguous 
and, therefore, objective, highly reproducible and easily exchangeable between laboratories. 
A practical disadvantage of MLST remains the relatively high cost of sequencing multiple 
targets, which could partially explain why MLST has not replaced the conventional PCR ribo-
typing in many European laboratories [55].
The analysis of recent scientific literature has revealed the main clinical applications of MLST. It is 
very important to first analyze the spread of epidemic strains, including the hypervirulent ones. 
This has been done, e.g., by researchers from Latin America, who have found that, in Chile, the 
most prevalent subtype (near to 80%) is subtype 1, related to the hypervirulent strain NAP1/027/
ST1. The MLST analysis was capable of describing a high similarity (73%, respectively) of this sub-
type with nine different other subtypes, characterized by a similar 117 bp deletion (in the tcdC gene) 
[49]. The spread of epidemic strains of C. difficile has been also studied on Czech isolates, using the 
MLST [80]. Kuwata et al. have claimed that in their first study from Japan, based on MLST, both 
toxigenic and nontoxigenic C. difficile strains showed high genetic variation and that drug resis-
tance was more likely related to toxigenic strains [93]. Some authors have used the MLST and have 
found that the ICU-acquired toxigenic C. difficile was not linked to those detected on admission. 
The active screening for toxigenic C. difficile was not considered to be a  resource-efficient measure 
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in settings with a low prevalence of colonization [86]. Another application of the MLST usage was 
to evaluate the dissemination of clones in hospitals and breeding-farms or a contamination in the 
slaughter-house, and the probability of interspecies transmission [94].
3.2.2. Whole genome sequencing (WGS)
Whole genome sequencing (WGS) is another sequence-based assay besides MLST, which 
has emerged as a promising sequence-based technique since it allows the detection of 
variations between C. difficile strains by, for example, single nucleotide polymorphisms 
(SNPs) analysis [95]. A study performed in England, using the WGS technologies to iden-
tify SNPs, identified three sublineages of C. difficile RT017 circulating in London. Like the 
notorious RT027 lineage, which has caused global outbreaks of C. difficile infection since 
2001, the lineage of toxin-defective RT017 strains appears to be continually evolving [96]. 
Even more, a team from Switzerland has developed a double locus sequence typing (DLST) 
scheme as a tool to analyze C. difficile isolates. The results of DLST were compared with 
the ones from MLST: DLST had a higher discriminatory power compared with MLST and 
successfully identified all isolates of the study. The main advantage of DLST is including 
the absence of DNA extraction (polymerase chain reaction PCR is performed on colonies), 
no specific instrumentation, the low cost, and the unambiguous definition of types [97].
4. The new epidemiology of C. difficile spread
In the past 20 years, the use of antibiotics and, in many countries, their overuse are the main causes 
of the extended spread of hyper virulent and multidrug-resistant strains of C. difficile, related to 
the 027 ribotype, as well as to many others. All methods try to rapidly identify the infected strain, 
but there are no solid arguments in differentiating between infection and colonization (positive 
C. difficile diagnosis, in the lack of symptoms). An excellent synthesis regarding colonization (car-
riage) and its role as a source of infection was published recently by Furuya-Kanamory et al.; the 
need of colonized patient identification is obvious: their prevalence is higher than in symptomatic 
cases; they can become a dangerous source of infection, and preventive methods must target 
them [98]. The cited study also made a vast synthesis of prevalence colonization rate over the 
world, which varied in large limits: 0–15% for healthy adults, almost 30% in colonized patients 
with nontoxigenic strains, and 0–51% in elderly residents of healthcare institutions [98].
Clinical and epidemiological data must be taken into consideration in this differentiation. 
The new rapid phenotypical and genotypical methods were a real support for the laboratory 
diagnosis that, in recent years, was able to rapidly identify the etiology of CDI; the need for 
rapid identification is related to the patients’ treatment and to the preventive measures. The 
alarming increase of cases is related to the highly virulent strain circulation growth and to 
these new sensitive and specific methods that increased the rate of positive diagnosis. All 
these factors have led to declaring CDI a public health problem [13, 23, 99]. The prevalence 
of CDI increased especially since 2003 (in the Quebec study, from Canada, this was fourfold 
times higher than before) [23]. Later, new reports from North America and Europe [7, 55] have 
claimed the spread of ribotype 027 strains, highly virulent and resistant to  fluoroquinolones, 
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as the main cause of this increasing prevalence. If medical care-associated infections were, 
from the beginning, the main cause of these alarming phenomena, other studies have clearly 
demonstrated the common origin for about one quarter of the cases (Lessa et al., cited by 
Burnham and Carroll [13]).
5. Commercially available real-time PCR test
In the last two decades, the laboratories have focused on using commercial kits, which have 
many advantages when compared to “in house” methods. We have chosen the real-time PCR 
tests, approved by the FDA, and they seem to be the most commonly used around the world, 
due to their performances.
The commercially available, real-time PCR tests for C. difficile diagnosis include the BD 
GeneOhm Cdiff (BD Diagnostics; San Diego, CA, USA) (target tcdB gene), Prodesse 
ProGastro Cd (Gen-Probe Inc.; San Diego, CA, USA) (target tcdB gene), Xpert C. difficile 
(Cepheid; Sunnyvale, CA, USA) (target tcdB gene and binary toxin), and Illumigene C. dif-
ficile (Meridian Biosciences; Cincinnati, OH, USA) (target tcdA gene), Real-Time PCR tests. 
Compared to the Cytotoxicity Neutralization Assay Culture (CNAC) and/or to the toxigenic 
culture, the PCR assays have been reported with sensitivities and specificities ranging from 
77 to 100% and 93 to 100%, respectively [20, 86]. These tests have been demonstrated as being 
similar or even more efficient when compared with CCNA for children stool samples [86].
The FDA approved a list of nucleic acid-based tests, which analyze variations in the sequence, 
structure, or the expression of the deoxyribonucleic acid (DNA) in order to diagnose infec-
tion with an identifiable pathogen, including C. difficile. (http://www.fda.gov/medicaldevices/
productsandmedical procedures/invitrodiagnostics/ucm330711.htm) [96].
The consultation of PubMed has allowed us to select 114 articles: 3 articles that used IMDx 
C. difficile for Abbott m2000 test, 2 with BD Diagnostics BD MAX Cdiff Assay, 2 with Quidel 
Molecular Direct C. difficile Assay, 3 with Verigene C. difficile Nucleic acid Test, 4—Portrait 
Toxigenic C. difficile Assay, 3—Simplexa C. difficile Universal Direct Assay, 8—Xpert C. difficile/
Epi, 27—Illumigene C. difficile Assay, 54—Xpert C. difficile, 3—ProGastro Cd Assay, and 5—
BD GeneOhm C. diff Assay.
For this short presentation, we have chosen the latest references that offered the most elo-
quent data regarding sensitivity, specificity, and, if available, positive predictive value and 
negative predictive value (Table 3) [101–111].
One feature of these articles is that they compare different platforms and analyze samples from 
different medical centers, and this action favors the evaluation of the test’s accuracy and repro-
ducibility. The sensitivity and the rapidity of the NAATs are excellent and fast (e.g., 90 min 
using Portrait Toxigenic test, or 65 min GeneXpert for 80 samples, simultaneously) making 
them reliable methods for the direct detection of tcdA and/or tcdB in stool specimens, compared 
with the toxigenic culture [100, 101]. Some differences in the sensitivity of the NAATs may 
partly depend on the number of toxigenic C. difficile in stool specimens. Considering the rapid-
ity and the high specificity of the real-time PCR assays compared to the toxigenic culture, they 
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can be used as the first test method for C. difficile infection/colonization. However, additional 
efforts should focus on the discrimination between infection and colonization. According to the 
overall performance of these assays, these results support the routine use of the said platforms 
for the detection of the toxigenic C. difficile in the clinical laboratories, a fact that will have a pos-
itive impact on patient care. Moreover, the Verigene CDF test is a novel nucleic acid microarray 
References Country Method Sensitivity Specificity
[101] Korea Xpert 90.0% 92.9%
Max 86.3% 89.3%
IMDx 84.3% 94.4%
Illumigene 82.4% 93.7%
[106] Korea Xpert 82.8% 98.8%
BD MAX 81.6% 95.8%
IMDx 62.1% 99.4%
[103] New York, USA BD Max Cdiff assay (Max) 96.9% 95%
Abbott m2000 assay (IMDx) 92.8% 100%
[104] Washington, Seattle Verigene CDF 95.2% 99.4%
Simplexa Universal Direct assay 87% 100%
BD MAX 87% 98.8%
[107] Heidelberg, Germany BD MAX Cdiff assay 90.5% 97.9%
Xpert C. difficile test 97.3% 97.9%
[108] USA Lyra assay on the SmartCycler II 82.1% 98.8%
ABI 7500 Fast DX 96.9% 85.7%
ABI QuantStudio DX 89.3% 99.0%
[109] California, USA Simplexa Universal Direct 98% 96%
AmpliVue assays 100% 100%
[105] Japan Verigene CDF test 96.7% 97.4%
[102] USA Portrait toxigenic Clostridium difficile 
assay
98.2% 92.8%
[110] California, USA Early prototype core molecular 
mirroring nuclear magnetic resonance 
detection platform (Mentor-100)
88.4% 87.0%
[111] Chicago, IL, USA Wampole toxin A/B EIA 85.4% 90.9%
CdQCC (GDH antigen) 95.8% 89.6%
BD GeneOhm 100% 100 %
Progastro Cd RT-PCR 93.8% 99.3%
Table 3. Characteristics of the FDA-approved tests for the detection of Clostridium difficile.
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that reliably detects both C. difficile toxins A and B in unformed stool (liquid) specimens and 
appears to adequately identify the ribotype 027 isolates [93, 104]. Another advantage is that 
sample processing is minimal, these tests having proved to be simple, cost-efficient, and with 
broad applicability to panel-based approaches, potentially simplifying the workflow [105].
Another application of these assays is the possible reporting of the DNA load of toxigenic 
C. difficile in the stool sample, which may represent a solution. Using the Xpert platform, 
most samples with discrepant results had C. difficile concentrations below the illumigene 
limit of detection. The significance of the low-level C. difficile detection needs to be fur-
ther investigated [105]. The estimated cost avoidance provided by a more rapid molecular 
diagnosis can be outweighed by the cost of isolating and treating PCR-positive/cytotoxin-
negative patients [103, 104]. The costs, the clinical consequences, and the impact on the 
nosocomial transmission of treating and/or isolating patients—positive for toxigenic C. dif-
ficile by PCR but negative for in vivo toxin production—worth further study. Diagnostic 
algorithms combining immunoassays and NAATs could also improve the specificity and 
reduce the global cost of this analysis [108–110].
In a recent study from 2014, Deak et al. [109] summarized the efficiency of two test cleared by 
the FDA (Simplexa Universal Direct and AmpliVue C. difficile Assay) having as references the 
Meridian Illuminigene Assay and the toxigenic C. difficile culture. In short, the best results were 
obtained with Simplexa (sensitivity 98%; limits: 88 ÷ 99.9), with short specimen preparation 
time, as AmpliVue (3 min, respectively), a small difference regarding the total time of the pro-
cedure (73 min versus 68 min for Illuminigene, and 91 min for AmpliVue), and only 8 min for 
hands-on time (versus 18, and 11 min for Illuminigene and AmpliVue, respectively). Both evalu-
ated tests showed the same specificity (100%; limits: 96.9 ÷ 100). In conclusion, better parameters 
regarding the handling time, the higher sensitivity, and the possibility to use the Simplexa plat-
form for other tests from Focus Diagnostics, recommend the kit for large laboratories with high 
sample numbers; the good performances of the AmpliVue can also be taken into consideration, 
when rapid and sensitive methods must be used for the C. difficile infection diagnosis [109].
6. Biological molecular methods for the characterization of C. difficile 
multidrug-resistant (MDR)  strains
The antibiotic resistance explains CDI and changes the therapeutic scheme of these cases. 
New patterns of C. difficile strains encourage the spread and persistence of these strains in 
healthcare facility settings; for this reason, the surveillance of resistance and the molecular 
characterization of these mechanisms are very important in CDI control and prevention 
[111]. Both conjunction [112] and translocation of the genetic mobile element CTn5 [113] were 
described. The genetic mechanisms were much better understood and easier to study after 
630 strain genome sequences [114] and resequencing studies. In a recent study, van Eijk et 
al. [114] analyzed the C. difficile laboratory strain 630Δerm and demonstrated, for the first 
time, the analysis of major methylation patterns for any C. difficile strain. In this research, the 
authors revealed that in addition to insertions, deletions, and SNPs, the CTn5 element moved 
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from its original location within the CD1844 to the rumA gene, in its isolate. This molecular 
genetic study highlighted that the major rearrangement has important implications for the 
redistribution of strains with highly mobile genomes and that, even though it is not related 
to direct studies regarding the antibiotic resistance of C. difficile, it argues for the complete re-
sequencing of common lab strains in each laboratory [113].
The complete genome sequences of C. difficile have made it possible to study the mobile 
genetic elements (transposons or transposable elements). This analysis describes that about 
11% of the C. difficile genome consists of mobile genetic elements, the majority being conjuga-
tive transposons; their presence is at the origin of virulence, antibiotic resistance, synthesis of 
different surface protein, and microorganism-host regulation-binding capacities [114]. The 
horizontal genetic transfer of these transferable elements between species or between strains 
of C. difficile is the main cause of such successful spreading, especially in healthcare facilities, 
as well as within the community.
The interest in such studies started with the worldwide spread of the highly virulent RT027 and 
of other ribotypes, which explain the CDI treatment failure. Generally speaking, the resistance 
phenomena are the consequences of antibiotic treatment, especially clindamycin (CLI), cephalo-
sporins (CFS), and fluoroquinolones (FQs), even though all antibiotics are theoretically capable 
to be the cause of CDI, in parallel with other risk factors (previously listed). The first antibiotics 
associated with CDI was CLI, a large broad spectrum antibiotics, with bacteriostatic activity, 
for which C. difficile demonstrated a high resistance level (more than 90%) [60]. The relative risk 
(RRs) for C. difficile acquisition is 9.0 for CLI, varying in large limits for CFs (from 7.8 for cefa-
clor, to 36.2 for cefotaxime), with lower risks for β-lactams (2.0 for penicillin, to 22.1 for ampi-
cillin and amoxicillin-clavulanic acid association) [5]. Even though the FQs have been used 
since 1988, their implication in CDI was described in the last 10 years (Sunenschine et al., cited 
by Bartlett and Gerding [5]). The most studied strains that belong to the RT027 demonstrated 
a high-level resistance to the FQs [7]. An excellent synthesis regarding the C. difficile antibiotic 
resistance and associated RTs was recently published by Spigaglia, in 2016 [61]. Although for 
the antibiotic susceptibility studies, the most frequent methods are the agar dilution (AD) and 
the epsilometer test (Etest), ribotyping is a supportive method that classified the strains, to 
connect infection/microorganism’s source/sources with secondary cases, in order to establish 
and implement the most appropriate prevention methods. Other methods can be used to study 
the genetic mechanisms of antibiotic resistance and their genetic horizontal transfer (by con-
junction, or conjugative-like processes), or with the support of bacteriophages in transduction, 
including mobile genetic elements, as support for pathogenicity, antibiotic resistance, and envi-
ronmental survival capacity [116–118]. Recent protocols were tested for the genetic manipula-
tion of C. difficile genome and future researches will be able to continue this new approach [119].
The rate of antibiotic resistance varied between different studies depending, most probably, 
on the antibiotics policy and the spread of different C. difficile strains, in various regions. A 
large synthesis of 30 studies dating from 2012 to 2015 [115] revealed that resistance to CLI 
and CFs is higher than 50% (55 and 51%, respectively), with a similar percent for ERY and 
FQs (47%). One of the most used classes of antibiotics, the cephalosporins (CFs), is the source 
of many cases of CDI; the new CFs, with a wider antibiotic spectrum and more recently intro-
duced in therapy, will induce the resistance phenomenon after several years of use. Thus, 
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the second-generation cephalosporin (cefotetan/CTT and cefoxitin/FOX) level of resistance is 
about 80% and, for the third generation, recently introduced to the market (e.g., ceftriaxone/
CRO and cefotaxime/CTX), the level of resistance has not yet reached 40% [115]. Although 
the phenomenon was highlighted by numerous strains resistant to CFs, the resistance mech-
anism is not completely understood. The strains belonging to different RTs (027 and to others 
ribotypes as it follows: 001, NAP1, 2, 4, and 6 [identified by PFGE], 002, 014, 017, 018, 053, 078, 
etc.) and C. difficile seem to be “constitutively resistant” to CFs, even though the main cases 
of CDI were described after CFs therapy, having different minimum inhibitory concentra-
tions (MICs) to different CFs. These different MIC values are probably due to drug-resistant 
strains. The WGS 630 strain analysis shows 25 coding sequence (CSs); their presence is not 
constant in all strains, the percentage of identity ranging between 73 and 100% [115].
Not infrequently, the growing alarming statistic indicators (incidence, prevalence, etc.) are 
the starting point of some research that explains the epidemiological phenomenon using 
molecular biology techniques. Looking to CDI incidence dynamics, Clabots et al. explained 
the increased incidence of CDI cases in 1985, at the Minneapolis Veterans Administration 
Medical center (from 7.1 to 17.3/month), by highlighting a cryptic plasmid of 3.1 kilobases 
(kb), present exclusively in clindamycin-resistant strains and absent in sensitive isolates. 
The identification of this plasmid was carried out by restricting endonuclease digestion and 
Southern blot hybridization, but the authors failed in their purpose to identify the source of 
these strains and plasmid mechanism acquisition [120].
A large pan-European longitudinal surveillance of antibiotic resistance, conducted by 
Freeman J, et al. [122] enrolled around 1000 strains from 22 countries and 39 sites. Nine hun-
dred and fifty-three strains were tested for PCR ribotyping, toxins, and antibiotic suscep-
tibility for metronidazole (MTZ), vancomycin (VAN), fidaxomicin (FDX), rifampicin (RIF), 
moxifloxacin (MOX), clindamycin (CLI), imipenem (IM), chloramphenicol (CH), and tige-
cycline (TIG). CL, MOX, and RIF resistance levels varied (50, 40, and 13%, respectively) and 
were evident in many RTs. The most frequent RTs registered were 027 (12%), 001/072 (9%), 
078, and 014 (8% each). MTZ, VAN, and TG were active in almost all cases, with a very low 
resistance level (2.18, 3.16, and 0.44%, respectively). One strain from UK (belonging to RT106) 
had a MIC for MTZ, 8 mg/L, and 20 strains demonstrated a reduced MTZ susceptibility, while 
11 of them were RT 027. The reduced VAN susceptibility was very rare; four countries (the 
Czech Republic, Ireland, Latvia, and Poland) sent strains with MIC of 4 mg/L, Italy and Spain 
submitted different RTs with VAN reduce susceptibility, including resistant strains, belong-
ing to RTs 027, 126, 356, and 001/007 [121]. The highest MIC values for VAN were determined 
for Rt 018 and 356.
Because the rates of treatment failure and recurrences have increased after MTZ and VAN cure, 
their replacement with different antibiotics was suggested. Rifamycins, like rifaximin (RFX) and 
fidaxomicin (FDX), a new bactericidal narrow spectrum macrocyclic antibiotic can be alternative 
therapies. Using antibiotic susceptibility test interpretative criteria, scientists proposed the use of 
rifampin (RIF) as an antibiotic related to RFX. The extrapolated literature data (from 2008 to 2012), 
from six relevant studies [115], show that 11% of C. difficile strains isolated from different clini-
cal cases demonstrated resistance to RIF, mainly because this antibiotic is the drug of choice for 
tuberculosis treatment in many countries. All strains from Italy belonged to RT046, and the stud-
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ied strains were isolated from TB patients with long RIF treatment [115]. In a study from Poland, 
from 2014, that characterized the pattern of susceptibility and ribotype association [121] for 83 
strains, the majority belonged to RT027 (57.8%), 25.3% to RT176, and 16.9% to others. The major-
ity of strains (85.5%) were resistant to erythromycin (ERY), more than a quarter percent (27.7%), 
resistant to CLI, with high MIC (greater than 256 mg/L). A high percent (83.1%) from all 83 strains 
was resistant to MOX, 87.9% resistant to imipenem (IMP), and only 2.4% to tetracycline. MTZ and 
VAN seem to continue to be efficient, having a low MIC
90
 value (0.75 mg/L) for both antibiotics. 
The most resistant strains belonged to RT027 and 176, with a MIC for ERT higher than 256 mg/L; 
the majority (95.2%) of RT176 strains were co-resistant to ERY and CLI. All strains resistant to ERY, 
MOX, and RIF belong to RT027 (18% strains respectively), and MDR strains (defined as strains 
resistant to at least three classes of antibiotics) were established for 71 strains (85.5%) [119] a per-
cent that is an alarming phenomenon.
It is obvious that all articles from previous years that have studied the resistance patterns of 
C. difficile strains from clinical samples, animal, and environmental sources [108, 109, 111, 
112, 120–131] from Europe, North America, and South-East Asia were designated not only to 
describe these patterns and their dynamics but also to classify them as RTs, to have a complete 
description of spread and risk for CDI, for higher virulent and MDR strains, too. Different 
studies have tried to describe, by different biological molecular methods, the C. difficile strain 
resistance mechanisms for cephalosporins, macrolide-lincosamide-streptogramin B (MLS
B
) 
family, fluoroquinolones, including for antibiotics useful in the treatment of CDI t (e.g., met-
ronidazole, vancomycin, rifamycins, and fidaxomicin); excellent syntheses regarding these 
mechanisms were recently published [61]. Having such a vast view on the evolution of antibi-
otic resistance to classical and new antibiotics, new strategies to limit this phenomenon could 
be designed and implemented to reduce hospitalization days, healthcare costs, and, not least, 
the emergence of new cases, potentially fatal.
7. Comparison of molecular biological methods
Nowadays, the revolution in the biological molecular field has generated a long list of methods 
and commercial kits, all these being found in numerous studies. Patient studies on different 
risk groups, reviews of literature, including meta-analyses and book chapters have been pub-
lished in recent years, regarding the new phenomenon, CDI. The increasing incidence, the 
morbidity, and mortality by CDI in the world stimulate scientists to find the cause and solu-
tions. Starting from years ago and even today, EIA and GDH for toxins and antigen detection 
were largely used but the lack of sensitivity of these methods imposed the search for new 
solutions. In the last 30 years, the PCR-based methods have found numerous practical applica-
tions for diagnosis, disease surveillance and, last but not least, for the study of antibiotic resis-
tance, including for the highly virulent C. difficile strains. The main criteria to reassess variants 
of molecular biology tests are discriminatory power, reproducibility, technical difficulty, time 
needed to perform them, their cost-benefit ratio, the ease of interpreting the results, and data 
inter-comparison between laboratories [24]. Starting from such criteria, Dingle and MacCallenn 
established that the restriction fragment techniques (REA, PFGE, and toxinotyping) have very 
Clostridium Difficile - A Comprehensive Overview92
good reproducibility and discriminatory capacities, with less power for the toxinotyping, for 
the second criteria [33]. PFGE, which needs a longer time, is more expensive and it is desig-
nated for laboratory expertise because of the difficulties in inter-laboratory comparison [13, 33].
For years, different studies have concluded that REA and PGFE present a comparable dis-
criminatory capacity, useful in epidemiological large studies regarding C. difficile typing iso-
lates and that ribotyping has a less discriminatory capacity [33].
Second major laboratory methods are based on PCR amplification (ribotyping, REP-PCR, 
MLVA, and AP-PCR). From this list, ribotyping seems to fulfill all criteria and, close to it, 
MLVA, even though it needs a longer time [33].
In the future, sequence-based methods (MLST, slpA, TRST, and WGS) will probably become 
the key to answer difficult questions, such as strains trace, outbreaks sources, and so on, even 
though, currently, these are mainly dedicated to research laboratories since they are character-
ized by high technicity, high cost, and time, as well as by difficulties relating to the inter-com-
parison between laboratories. One question in the daily activity has to do with the selection of 
the appropriate genotyping method. To answer it, it is necessary to list their reference character-
istics such as validity (to be applicable to all studied strains), discriminatory capacity (to be able 
to make the difference between unrelated strains), and reproducibility (this must be applicable 
between and within laboratories). Other criteria are related to difficulties and the step number 
of the method, rapidity, and to the cost-efficiency ratio. With this choice, we must take into con-
sideration the purpose of genotyping: in the rapid tracking of local outbreaks, MLVA seems to 
be the most useful method and, in long epidemiological studies, MLST, PFGE, and WGS [35].
WGS will soon be the mandatory method to carry out quality multicenter studies, as 
ECDC has proposed minimum four major infections as follows: carbapeneme- resistant 
Enterobacteriaceae, Neisseria gonorrhoeae, C. difficile, and MRSA (methicillin-resistant S. aureus). 
According to the ECDC’s experts, WGS “will improve the accuracy and effectiveness of dis-
ease surveillance, outbreak investigation and evaluation of prevention policies by enhanced 
assessment of disease and drug resistance transmission dynamics” [130]. Even though WGS 
can offer data (e.g., “in silico” design microrestriction profile for enzymes used in different 
techniques) for sequence-based and nonsequence-based genotyping methods, it remains a 
cumbersome test, expensive and dedicated only to high expertise laboratories [35].
8. Comparison between classical and modern methods
After the FDA has approved the standardized methods/tests, many authors have tried to 
find answers to different questions: Are the methods of molecular biology a better variant 
and more cost-effective than the phenotypic methods? In many countries, even with a good 
technical infrastructure and highly qualified personnel, EIA and GDH are the most useful 
methods for rapid CDI diagnosis. These tests and others, based on the phenotypic character-
ization (e.g., slide agglutination for serotyping, antibiotic susceptibility pattern), have some 
disadvantages such as a low reproducibility and the incapacity to differentiate between large 
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numbers of isolates. Different study groups underline that EIA for A and B toxin detection has 
a low sensitivity and poor specificity [22, 131]. As we know, the efficiency of the test depends 
on the capacity of test itself to trace the smallest amounts of antigens in samples with higher 
specificity (these are dependent on the antibody clonality, on the binding power to EIA sup-
port, etc.) and on the difference in strain circulation in different geographical areas. For some 
EIA kits, sensitivity was about 15% for some ribotypes [127]. One very useful test is DGH that, 
in comparison with the toxigenic culture, showed a sensitivity similar to the real-time PCR for 
RT027, but the lowest sensitivity for non-027 infections; the sensitivity of GDH determination 
may be 70%, in comparison with the Gene-Xepert Assay [127]. GDH positive results must be 
confirmed with a different method (e.g., culture cytotoxicity assays, EIA, or NAATs) because 
this antigen can provide such results for both toxigenic and nontoxigenic strains.
Different authors, including professional society experts, recommend the two-step diagnosis, 
having GDH as a screening test and a follow-up test to confirm toxin presence. A recent meta-
analysis (Shetty et al., cited by Carroll and Loeffelholz [23]) has concluded that GHD is highly 
sensitive, with high negative predictive value and that it has conducted to the best results in the 
two-step algorithms. To avoid this second test for toxin detection, a new immunochromato-
graphic test (ICT) was proposed for both simultaneous detections. This ITC variant (Cdiff Quik 
Chek Complete; TechLab, Blacksburg, VA) has a good sensitivity for GDH, but a less good one 
for toxin detection (from 61 to 78%) and, for this reason, different laboratories use it in three-step 
diagnosis algorithm: GDH positive sample and toxin negative need to be retested by one NAAT.
On the other hand, different expert groups from Europe and USA [22, 131] strongly recom-
mend replacing EIA with more sensitive assays, in order to quickly identify the C. difficile 
infection (or colonization) and to rapidly implement the appropriate preventive measures. 
Caroll and Loeffelholtz [23] support this approach having as arguments the final cost, which 
is the lowest for laboratories that use more sensitive tests, and the reduced healthcare associ-
ated infection, as consequence of rapid and efficient preventive methods.
Nowadays, in many laboratories, EIA and PCR-based methods used for C. difficile diagno-
sis replaced cultivation—the best way to study antibiotic susceptibility from pure culture—
as source of future studies, including sequence analysis, but the toxigenic culture remains 
impractical, in relation to the time needed for end results.
As we have already briefly presented, the FDA has approved many NAATs, and different 
studies have concluded that such platforms have the highest sensitivity and that results are 
comparable between them. Contrary to this statement, we must note that the NAATs can 
detect conserved regions of A and/or B toxin genes, and not the toxin itself. For this rea-
son, these tests cannot differentiate between infection and colonization and, moreover, they 
require complex infrastructure and highly qualified staff, both of which are more expensive, 
and that future researches are necessary for a clear conclusion regarding their utility for diag-
nosing the infection in children [23].
Even though the laboratory methods applicable for the identification of C. difficile are diverse, 
their various disadvantages have imposed the use of new techniques, including strain iden-
tification by MALDI-TOF (matrix-assisted laser desorption/ionization-time-flight mass 
Clostridium Difficile - A Comprehensive Overview94
spectrometry) [13, 132–135]. The method has been recently introduced in the clinical labora-
tory practice to identify the bacteria and to describe the resistance profile to antibiotics [13]. 
MALDI-TOF is based on the identification of some molecules, on calculating flight time in a 
vacuum tube, after the first sample was co-crystallized on a matrix and irradiated with laser. 
Flight duration allows the calculation of the weight/load ratio for the detected ions, generat-
ing a spectrum that will be compared with a database, to identify the bacterium in the sample. 
Whole bacteria, as well as brute extracts, may be used as samples [132, 133].
Identification is based on comparing the profile of some unique proteins present in the bacte-
rial wall, thus becoming specific biomarkers, useful including in strain typing. Initially, Reil 
et al. have used the method to identify a limited number of ribotypes, including the highly 
virulent and the multidrug-resistant one (027 ribotype, respectively), based on the molecular 
weight of the selected proteins (between 2 and 20 kDa). Subsequently, Razarrdi and Akerlund 
have improved the method by selecting an initial wider range for the molecular weight of 
the selected proteins from 30 to 50 kDA followed by an analysis within the range used in 
the initial experiments (2–20 kDa), using ribotyping as a reference test by PCR. This way, for 
epidemiological purposes, typing C. difficile strains based on high molecular weight (HMW) 
might be combined with PCR ribotyping. In addition, by analyzing some surface proteins, 
involved in the attachment to specific receptors, MALDI-TOF would provide information 
related to the virulence of the infecting strain, including the immune response toward them 
and diseases severity [133].
By using MALDI-TOF, after obtaining the culture on chromogenic media, the diagnosis is 
more sensitive (from 94.7 to 100%) and more specific (from 79.7 to 100%), thus with significant 
statistical differences (p < 0.001). Furthermore, the technique allows the exclusion of false-
positive results obtained by using the chromogenic media, hence the role of MALDI-TOF 
as confirmatory test. The rapid detection (10 min) and the very low cost make the test more 
useful as an identification test, compared with molecular biology methods (e.g., 16S rRNA 
gene sequencing), including the control of nosocomial infections associated with antibiotics 
therapy [134, 135].
To draw a general conclusion, we can state that the best algorithm starts with GDH as a 
screening test, a confirmation of toxin presence using a highly sensitive test, ideally a NAATs 
variant, bearing in mind that GDH efficiency is related to the strain types from different geo-
graphical areas [13, 20, 23].
9. Future directions
The prevention of CDI involves many factors, starting with the correct diagnosis, but we 
should also think about prevention (contact/isolation), antimicrobial stewardship, and fecal 
bacteriotherapy [136].
In a recent report of the ECDC, the importance of defining CDI, recurrent CDI cases, and CDI 
case origin were mentioned. Also, ESCMID recommended the following possible algorithms 
for the CDI diagnosis:
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• Screening with NAAT, confirmation with toxin A/B EIA
• Screening with both GDH and A/B EIA toxin, optional confirmation with NAAT or toxi-
genic culture
• Screening with GDH EIA, confirmation with A/B EIA toxin, optional second confirmation 
with NAAT or toxigenic culture [137].
In recent years, quick methods—such as immunochromatography, which require less than 
30 min, thus being useful as a screening test—have been proposed for the diagnosis of CDI; 
however, future clinical studies are necessary. New technologies—such as multicapillary col-
umn gas chromatography, a quick method but with sensitivity and specificity values less than 
90%, a fact that requires the improvement of the method to increase accuracy—have been pro-
posed. Another proposal aims at associating the use of selective media with the Fluorescent 
In Situ Hybridization (FISH) test, which, during the same day, can identify the strain by typ-
ing, determine the resistance profile, and detect toxins, therefore, having a higher clinical rel-
evance, compared to other methods [135].
Like in other clinical situations, in which the diagnosis methods have switched to automati-
zation, there is also a need for standardization of C. difficile detection. The clinical validation 
of the assays on many samples, to easily compare and to rely on the results from different 
countries, is very useful. The surveillance protocol established by the ECDC will improve the 
case management and the preventive measures [137–139].
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